WANBURY | BH.IMMUN&BIO | WANBURY/ BH.IMMUN&BIO |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 22.2 | -7.4 | - | View Chart |
P/BV | x | - | 1.4 | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
WANBURY BH.IMMUN&BIO |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WANBURY Mar-23 |
BH.IMMUN&BIO Mar-23 |
WANBURY/ BH.IMMUN&BIO |
5-Yr Chart Click to enlarge
|
||
High | Rs | 90 | 52 | 172.8% | |
Low | Rs | 33 | 21 | 161.2% | |
Sales per share (Unadj.) | Rs | 152.8 | 10.3 | 1,478.6% | |
Earnings per share (Unadj.) | Rs | -3.2 | -3.9 | 82.5% | |
Cash flow per share (Unadj.) | Rs | 0.6 | -3.8 | -16.0% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | -10.5 | 20.4 | -51.5% | |
Shares outstanding (eoy) | m | 32.71 | 43.18 | 75.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.4 | 3.5 | 11.5% | |
Avg P/E ratio | x | -19.3 | -9.4 | 205.5% | |
P/CF ratio (eoy) | x | 100.8 | -9.5 | -1,061.2% | |
Price / Book Value ratio | x | -5.8 | 1.8 | -328.8% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 2,004 | 1,561 | 128.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 810 | 151 | 534.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,996 | 446 | 1,120.1% | |
Other income | Rs m | 10 | 11 | 95.1% | |
Total revenues | Rs m | 5,007 | 457 | 1,096.3% | |
Gross profit | Rs m | 225 | -161 | -139.9% | |
Depreciation | Rs m | 124 | 2 | 6,192.5% | |
Interest | Rs m | 214 | 71 | 303.0% | |
Profit before tax | Rs m | -103 | -223 | 46.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1 | -56 | -1.9% | |
Profit after tax | Rs m | -104 | -166 | 62.5% | |
Gross profit margin | % | 4.5 | -36.0 | -12.5% | |
Effective tax rate | % | -1.1 | 25.3 | -4.2% | |
Net profit margin | % | -2.1 | -37.3 | 5.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,222 | 358 | 341.2% | |
Current liabilities | Rs m | 3,204 | 940 | 340.7% | |
Net working cap to sales | % | -39.7 | -130.6 | 30.4% | |
Current ratio | x | 0.4 | 0.4 | 100.2% | |
Inventory Days | Days | 4 | 85 | 4.7% | |
Debtors Days | Days | 497 | 1,135 | 43.7% | |
Net fixed assets | Rs m | 1,742 | 1,262 | 138.1% | |
Share capital | Rs m | 327 | 432 | 75.7% | |
"Free" reserves | Rs m | -672 | 450 | -149.1% | |
Net worth | Rs m | -344 | 882 | -39.0% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 2,984 | 1,620 | 184.2% | |
Interest coverage | x | 0.5 | -2.2 | -24.1% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.7 | 0.3 | 608.1% | |
Return on assets | % | 3.7 | -5.9 | -62.3% | |
Return on equity | % | 30.2 | -18.9 | -160.0% | |
Return on capital | % | -32.2 | -17.2 | 187.0% | |
Exports to sales | % | 58.0 | 0 | - | |
Imports to sales | % | 20.5 | 14.5 | 141.7% | |
Exports (fob) | Rs m | 2,899 | NA | - | |
Imports (cif) | Rs m | 1,024 | 65 | 1,587.4% | |
Fx inflow | Rs m | 2,997 | 0 | - | |
Fx outflow | Rs m | 1,072 | 65 | 1,661.2% | |
Net fx | Rs m | 1,925 | -65 | -2,984.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 198 | 109 | 181.8% | |
From Investments | Rs m | -88 | 5 | -1,913.0% | |
From Financial Activity | Rs m | -320 | -147 | 217.4% | |
Net Cashflow | Rs m | -210 | -34 | 626.5% |
Indian Promoters | % | 30.6 | 59.3 | 51.6% | |
Foreign collaborators | % | 9.2 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 0.0 | - | |
FIIs | % | 0.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 60.2 | 40.8 | 147.8% | |
Shareholders | 13,087 | 35,313 | 37.1% | ||
Pledged promoter(s) holding | % | 92.5 | 0.0 | - |
Compare WANBURY With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | WANBURY | BH.IMMUN&BIO | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.85% | -0.57% | -0.57% |
1-Month | 6.79% | -2.21% | 0.07% |
1-Year | 281.42% | 22.70% | 52.18% |
3-Year CAGR | 18.46% | -10.99% | 14.04% |
5-Year CAGR | 47.89% | 28.45% | 19.13% |
* Compound Annual Growth Rate
Here are more details on the WANBURY share price and the BH.IMMUN&BIO share price.
Moving on to shareholding structures...
The promoters of WANBURY hold a 39.8% stake in the company. In case of BH.IMMUN&BIO the stake stands at 59.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of WANBURY and the shareholding pattern of BH.IMMUN&BIO.
Finally, a word on dividends...
In the most recent financial year, WANBURY paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
BH.IMMUN&BIO paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of WANBURY, and the dividend history of BH.IMMUN&BIO.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.